Pain Management

Pain affects 70–95% of ME/CFS patients and includes headaches, myalgia, arthralgia, and neuropathic pain. Pain in ME/CFS is likely mediated by central sensitization, neuroinflammation, and small fiber neuropathy (Chapter Neurological and Neurocognitive Dysfunction) rather than peripheral tissue damage, which has implications for treatment selection.

1 Analgesics

Simple analgesics provide modest relief for many patients but rarely achieve adequate pain control as monotherapy:

  • Acetaminophen (paracetamol): 500–1000 mg up to 4 times daily. Safe for most patients but limited efficacy for neuropathic pain. Avoid exceeding 3 g/day, particularly in patients with hepatic compromise
  • NSAIDs: Ibuprofen (200–400 mg), naproxen (250–500 mg). Useful for inflammatory pain, headaches, and myalgia. Long-term use carries gastrointestinal, renal, and cardiovascular risks; periodic use with gastroprotection is preferred. May paradoxically benefit ME/CFS through anti-inflammatory effects beyond analgesia
  • Topical agents: Diclofenac gel, capsaicin cream, or lidocaine patches provide localized relief without systemic side effects. Appropriate for focal myalgia or arthralgia

2 Neuropathic Pain Medications

Given the central sensitization and small fiber neuropathy underlying much ME/CFS pain, neuropathic pain agents are often more effective than traditional analgesics:

  • Gabapentin: 100–1200 mg in divided doses, titrated slowly. First-line for neuropathic pain in ME/CFS due to dual benefit on pain and sleep. Start at 100 mg at bedtime to minimize cognitive effects
  • Pregabalin: 25–300 mg in divided doses. Similar mechanism to gabapentin with more predictable pharmacokinetics. FDA-approved for fibromyalgia
  • Duloxetine: 20–60 mg daily. An SNRI with FDA approval for fibromyalgia, diabetic neuropathy, and chronic musculoskeletal pain. May improve fatigue alongside pain in some patients. Nausea and activation side effects limit tolerability
  • Low-dose naltrexone (LDN): 1.5–4.5 mg at bedtime. Growing evidence for efficacy in fibromyalgia and preliminary evidence in ME/CFS. Proposed mechanism involves microglial modulation and reduced central sensitization. Well-tolerated; vivid dreams are the most common side effect

3 Opioids

Opioid use in ME/CFS is controversial and generally discouraged as routine treatment:

  • Risks: Dependence, tolerance, opioid-induced hyperalgesia, cognitive impairment, constipation (worsening GI dysfunction), and immune suppression—all particularly concerning in ME/CFS patients
  • Limited efficacy: Central sensitization pain responds poorly to opioids compared to neuropathic agents
  • Potential role: In patients with severe pain refractory to all other interventions, low-dose opioids (e.g., tramadol 50–100 mg, low-dose buprenorphine) may be considered under specialist supervision with clear monitoring and discontinuation criteria
  • Tramadol: Has dual opioid and serotonin–norepinephrine reuptake inhibition. Some ME/CFS patients report benefit; serotonin syndrome risk with concurrent SSRIs/SNRIs must be monitored
CautionWarning: Opioid Prescribing in ME/CFS

If opioids are prescribed, patients must understand that these are for pain management, not energy improvement. Opioid-mediated pain reduction may enable patients to exceed their energy envelope, paradoxically worsening ME/CFS through PEM.

4 Non-pharmacological Pain Management

Non-pharmacological approaches are important adjuncts to medication, particularly given the central sensitization component of ME/CFS pain:

  • Adapted physical therapy: Gentle, sub-threshold exercise guided by a physiotherapist experienced with ME/CFS. Focus on maintaining range of motion and preventing contractures rather than progressive strengthening. All activity must remain within the energy envelope
  • Gentle stretching: Brief (5–10 minute), low-intensity stretching sessions can reduce myalgia and maintain flexibility. Yoga nidra or restorative yoga positions (performed lying down) may be tolerated by moderate–severe patients
  • Heat therapy: Warm baths (if tolerated), heating pads, or infrared therapy can relieve myalgia and joint stiffness. Caution in patients with autonomic dysfunction, as heat may worsen orthostatic intolerance
  • Cold therapy: Ice packs or cooling wraps for acute pain flares, particularly headaches and localized inflammation
  • TENS units: Transcutaneous electrical nerve stimulation provides modest pain relief for some patients with minimal energy cost or side effects. Portable units allow use during rest periods
  • Manual therapy: Gentle massage, myofascial release, or craniosacral therapy may provide temporary relief. Vigorous massage can trigger PEM and should be avoided